[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Guangxi Medical University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":186},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,45,81,110,132,161],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100636083","comparison-of-partial-stomach-partitioning-and-conventional-gastrojejunostomy-for-the-treatment-of-gastric-outlet-obstruction-in-advanced-gastric-cancer-100636083",false,"NCT07561073","Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer","A Multicenter Randomized Controlled Trial Comparing the Safety and Efficacy of Partial Stomach-Partitioning Gastrojejunostomy (SPGJ) Versus Conventional Gastrojejunostomy (CGJ) for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer","Inclusion Criteria:\n\n1.Patients and their families were fully aware of this study and voluntarily signed informed consent ; 2.Age 18-75 years old ( including 18 and 75 years old ) ; 3.Distal gastric cancer ( cT4bN + M0 \u002F T3-4N + M1, stage IV ) with locally unresectable, distant metastasis or peritoneal metastasis confirmed by pathology and unable to undergo radical surgery ; 4.Complicated with digestive tract obstruction ( gastric retention confirmed by upper gastrointestinal radiography or gastroscopy, and GOOSS score ≤ 1 ) ; the ECOG score was 0-2 points, and there was no deterioration within 7 days ; 6.ASA score I-III ; 7.No previous anti-tumor therapy ( such as radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc. ) :\n\nThe functions of important organs meet the following requirements :\n\n(a) absolute neutrophil count ≥ 1.5 × 109 \u002F L, white blood cell count ≥ 4.0 × 109\u002FL; （b) Platelet ≥ 100 × 109 \u002F L ; （c) Hemoglobin ≥ 60g \u002F L ; （d) TBIL ≤ 1.5 times ULN ; （e) ALT and AST ≤ 2.5 times ULN ; （f) urea \u002F urea nitrogen ( BUN ) and creatinine ( Cr ) ≤ 1.5 × ULN ( and creatinine clearance rate ( CCr ) ≥ 50mL \u002F min ) ; （g) Left ventricular ejection fraction ( LVEF ) ≥ 50 % ; the corrected QT interval ( QTcF ) by Fridericia method was less than 470 ms. （i) INR ≤ 1.5 × ULN, APTT ≤ 1.5 × ULN. 9. women of childbearing age need to take effective contraceptive measures ; 10.No other surgical contraindications ; 11.good compliance, with follow-up.\n\nExclusion Criteria:\n\n1. Unable to comply with the research program or research procedures ;\n2. Patients with other malignant tumors within 5 years before enrollment, except for basal cell or squamous cell carcinoma of the skin after radical resection, or cervical carcinoma in situ ;\n3. Patients with active autoimmune diseases or a history of autoimmune diseases within 4 weeks before enrollment ;\n4. Previously received allogeneic bone marrow transplantation or organ transplantation ;\n5. Cardiovascular diseases with significant clinical significance, including but not limited to acute myocardial infarction, severe \u002F unstable angina pectoris or coronary artery bypass grafting within 6 months before enrollment ; congestive heart failure New York Heart Association ( NYHA ) grade \\> 2 ; ventricular arrhythmia requiring drug treatment ; lVEF ( left ventricular ejection fraction ) \\\u003C 50 % ;\n6. Active or uncontrolled severe infection ( ≥ CTCAE V5.0 grade 2 infection ) ;\n7. Known human immunodeficiency virus ( HIV ) infection. Patients with known clinical history of liver disease, including viral hepatitis \\[ known as hepatitis B virus ( HBV ) carriers must be excluded from active HBV infection, that is, HBV DNA positive ( \\> 1 × 104 copies \u002F mL or \\> 2000 IU \u002F ml ) ; it is known that hepatitis C virus infection ( HCV ) and HCV RNA positive ( \\> 1 × 103 copies \u002F mL ) ;\n8. pregnant ( pregnancy test positive before medication ) or breastfeeding women ;\n9. Any other disease with clinically significant metabolic abnormalities, physical examination abnormalities or laboratory abnormalities, according to the judgment of the researchers, it is reasonable to suspect that the patient has a state that is not suitable for enrollment ( such as having seizures and requiring treatment ), or will affect the interpretation of the results of the study, or put the patient at high risk ; the researchers considered that the patients were not suitable for inclusion in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},80,"ESTIMATED","INTERVENTIONAL",[24],"NA","The primary goal of clinical treatment is to relieve obstruction, restore oral feeding, improve nutritional status and improve quality of life in patients with advanced gastric cancer outflow tract obstruction. At present, the common surgical treatment for relieving obstruction is traditional gastrojejunostomy. Although the operation can relieve the obstruction, there are problems such as tumor-induced bleeding, anastomotic invasion, and high incidence of delayed gastric emptying after operation. Partitioned gastrojejunostomy effectively relieves obstruction by anastomosis of a part of the stomach to the jejunum, and isolates the tumor from the anastomosis, which is beneficial to food emptying and can reduce the risk of bleeding and anastomotic invasion. The safety and efficacy of these two procedures are still controversial, mainly because previous studies were retrospective studies or included a small sample size or enrolled patients with different pathological characteristics. The purpose of this study was to compare the safety and efficacy of separated and traditional gastrojejunostomy in the treatment of advanced gastric cancer outflow tract obstruction, and to provide the best choice for the treatment of advanced gastric cancer outflow tract obstruction.",[27],"Gastric Cancer",[29,30,31],"Gastric cancer","conventional gastrojejunostomy","Partial Stomach-Partitioning Gastrojejunostomy","RECRUITING","2026-05-31",{"date":35,"type":36},"2026-06-03","ACTUAL",{"date":38,"type":36},"2026-01-01",{"date":40,"type":21},"2029-01-01",{"name":42,"class":43},"Guangxi Medical University","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":57,"studyType":58,"phases":4,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":44},"100639284","multimodal-imaging-and-digital-pathology-for-prostate-cancer-prediction-100639284","NCT07614256","Multimodal Imaging and Digital Pathology for Prostate Cancer Prediction","A Multicenter Study of a Deep Learning Model Based on Spatial Registration of Multimodal Imaging and Digital Pathology for Predicting Clinically Significant Prostate Cancer","Inclusion Criteria:\n\n1. Subjects who are scheduled to undergo or have undergone prostate biopsy or radical prostatectomy.\n2. Subjects who have completed standard-of-care preoperative multiparametric MRI (mpMRI) and transrectal ultrasound (TRUS) examinations.\n3. Subjects with complete pathological diagnosis results available.\n4. Age between 40 and 90 years.\n5. Able and willing to provide written informed consent (for prospective cohort participants only).\n\nExclusion Criteria:\n\n1. Prior history of pelvic radiation therapy or radical prostatectomy.\n2. Incomplete or poor-quality mpMRI or TRUS images (e.g., motion artifacts, insufficient sequences).\n3. Concurrent other primary malignant tumors.\n4. Severe systemic diseases that may affect the evaluation of the prostate.\n5. Subjects with incomplete clinical or pathological data.\n6. Contraindications to MRI examination (e.g., incompatible metallic implants, severe claustrophobia).","MALE","40 Years","90 Years",{"count":56,"type":21},3000,"12 Years","OBSERVATIONAL","This is a multicenter observational study. A deep learning model integrated with multimodal imaging and digital pathology spatial registration is built based on preoperative multiparametric magnetic resonance imaging, transrectal ultrasound and postoperative digital pathological whole slide images. The study is designed to achieve accurate prediction of clinically significant prostate cancer and non-invasive risk stratification. Unnecessary prostate biopsy and overdiagnosis can be reduced to support the optimization of clinical diagnosis and treatment strategies.",[61,62],"Prostate Cancer (Diagnosis)","Clinically Significant Prostate Cancer",[64,65,66,67,68,69,70,71,72],"Prostate cancer","Clinically significant prostate cancer","Multiparametric Magnetic Resonance Imaging","Transrectal ultrasound","Digital pathology","Deep learning","Artificial intelligence","Spatial registration","Risk stratification","2026-05-25",{"date":75,"type":36},"2026-05-29",{"date":77,"type":36},"2025-05-30",{"date":79,"type":21},"2030-12-31",{"name":42,"class":43},{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":88,"enrollmentInfo":89,"targetDuration":4,"studyType":22,"phases":91,"briefSummary":93,"conditions":94,"keywords":98,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":44},"100625035","phase-3-adjuvant-tace-in-hcc-with-high-risk-recurrence-factors-100625035","NCT07417397","Adjuvant TACE in HCC With High-risk Recurrence Factors","The Efficacy and Safety of Adjuvant TACE in Radical Surgery for Hepatocellular Carcinoma With High-risk Recurrence Factors: A Phase III Randomized Controlled Clinical Study","Inclusion Criteria:\n\n* Eastern Cooperative Oncology Group performance status (ECOG PS) 0-1 at enrollment;\n* Child-Pugh class A or B7 (score 5-7);\n* having undergone radical hepatic resection at one of the study centers;\n* histopathologically confirmed HCC;\n* undergo hepatic angiography 4-8 weeks after surgery, with confirmation of no intrahepatic tumor staining;\n* have no prior systemic anti-tumor therapy for HCC;\n* have adequate organ and bone marrow function;\n* estimated life expectancy \\>6 months;\n* present with at least one high-risk factor for recurrence (such as tumor rupture; maximum tumor diameter \\>5 cm; multifocal tumors; microvascular invasion on postoperative pathology; Vp1\u002FVp2 portal vein invasion; lymph node metastasis confirmed by postoperative pathology; positive or narrow surgical margin; and Edmondson grade Ⅲ-Ⅳ differentiation).\n\nExclusion Criteria:\n\n* absence of pathological confirmation of HCC;\n* diagnosis of other malignancies within the 5 years prior to enrollment;\n* a history of hepatic encephalopathy, liver transplantation, pleural effusion, ascites, or pericardial effusion with clinical symptoms after curative hepatectomy, as well as a history of drug allergy, active pulmonary tuberculosis, active syphilis infection, autoimmune disease, or long-term glucocorticoid use;\n* participants who have experienced severe infections within 4 weeks before the first dose, or who have previously received systemic anti-tumor therapy;\n* pregnant or lactating women are ineligible for participation;\n* participants who are unable to comply with the treatment regimen or complete the follow-up requirements.","70 Years",{"count":90,"type":21},442,[92],"PHASE3","The 5-year recurrence rate after curative hepatectomy of hepatocellular carcinoma (HCC) remains as high as 70%. According to the Chinese Liver Cancer Staging (CNLC), transarterial chemoembolization (TACE) is strongly recommended as an adjuvant therapy after curative hepatectomy, aiming to reduce postoperative recurrence and ultimately improve overall survival. However, the effectiveness of such adjuvant postoperative therapy remains controversial. In contrast, guidelines from other countries or regions do not recommend adjuvant TACE after curative hepatectomy. This discrepancy may stem from the fact that adjuvant TACE primarily serves to detect intrahepatic residual lesions via digital subtraction angiography, rather than exerting preventive or therapeutic effects through the embolic agents or chemotherapeutic drugs themselves. This study will evaluate the impact of adjuvant TACE on recurrence-free survival in HCC patients with high-risk recurrence factors who have undergone curative hepatectomy. This study is a Phase III randomized controlled trial in which a total of 442 eligible participants will be randomized in a 1:1 ratio to either the adjuvant TACE group or the intensive follow-up group. The two groups will be compared with respect to recurrence-free survival, overall survival, incidence of treatment-related adverse events and serious adverse events, incidence of treatment discontinuation due to treatment-related adverse events or serious adverse events, median recurrence-free survival, and time to recurrence.",[95,96,97],"Hepatocellular Carcinoma","Adjuvant","Transarterial Chemoembolization",[99,100,101],"transarterial chemoembolization","hepatocellular carcinoma","adjuvant","2026-02-11",{"date":104,"type":36},"2026-02-18",{"date":106,"type":36},"2026-02-01",{"date":108,"type":21},"2029-12-31",{"name":42,"class":43},{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":117,"targetDuration":4,"studyType":58,"phases":4,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":44},"100547234","conversion-or-neoadjuvant-therapy-in-hepatocellular-carcinoma-100547234","NCT06405321","Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma","Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)","Inclusion Criteria:\n\n* Histologically or clinically confirmed diagnosis of HCC.\n* Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy.\n* Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1.\n* With Child-Pugh 5\\~7 scores.\n\nExclusion Criteria:\n\n* Concurrent with other malignancies within 5 years.\n* Incomplete medical data.\n* Follow-up time less than 3 months.",{"count":118,"type":21},2000,"This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.",[95],[122,123],"conversion therapy","neoadjuvant therapy","2026-01-13",{"date":126,"type":36},"2026-01-14",{"date":128,"type":36},"2019-01-01",{"date":130,"type":21},"2026-12-31",{"name":42,"class":43},{"id":133,"slug":134,"hasResults":11,"nctId":135,"briefTitle":136,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":139,"sex":16,"minAge":17,"maxAge":140,"enrollmentInfo":141,"targetDuration":4,"studyType":22,"phases":143,"briefSummary":144,"conditions":145,"keywords":147,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":44},"100613331","the-workplace-based-hypertension-management-program-100613331","NCT07265193","The Workplace-Based Hypertension Management Program","The Workplace-Based, Multicomponent Hypertension Management Program in Patients Aged 18-60 Years: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Adults aged 18-60 years\n* Newly diagnosed hypertension (per 2024 Chinese hypertension guideline criteria)\n* Employed in Kailuan Group workplace settings\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Severe cardiovascular or renal disease at baseline\n* Psychiatric disorders affecting compliance\n* Pregnant or lactating women\n* Participation in other intervention trials",true,"60 Years",{"count":142,"type":21},512,[24],"This study aims to evaluate the effectiveness of a workplace-based, multicomponent hypertension management program for newly diagnosed patients. Investigators will recruit 512 participants (256 pairs) from the Kailuan Study in Tangshan, China. Participants will be randomly assigned to receive a Workplace-based Multicomponent Hypertension Management Program or Standard Workplace Health Management. The primary objective is to assess improvements in blood pressure control and hypertension-related health behaviors.",[146],"Hypertension",[146,148,149,150,151],"workplace health","behavioral intervention","randomized controlled trial","Kailuan study","NOT_YET_RECRUITING","2025-12-02",{"date":155,"type":36},"2025-12-04",{"date":157,"type":21},"2026-01",{"date":159,"type":21},"2027-01",{"name":42,"class":43},{"id":162,"slug":163,"hasResults":11,"nctId":164,"briefTitle":165,"officialTitle":166,"acronym":4,"eligibilityCriteria":167,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":168,"enrollmentInfo":169,"targetDuration":4,"studyType":22,"phases":171,"briefSummary":174,"conditions":175,"keywords":4,"overallStatus":152,"whyStopped":4,"lastUpdateSubmitDate":178,"lastUpdatePostDateStruct":179,"startDateStruct":181,"completionDateStruct":183,"leadSponsor":185,"locationsCount":4},"100508272","phase-1-cadonilimab-in-the-treatment-of-recurrentmetastatic-nasopharyngeal-carcinoma-100508272","NCT05898256","Cadonilimab in the Treatment of Recurrent\u002FMetastatic Nasopharyngeal Carcinoma","A Single-arm, Multicenter, Phase II Study Evaluating the Efficacy and Safety of Cadonilimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma","Inclusion Criteria:\n\n1. The subject must sign the written informed consent form (ICF) voluntarily；\n2. Age ≥18 years and ≤65 years；\n3. Subjects with histopathological diagnosis of nasopharyngeal carcinoma；\n4. Primarily metastatic (stage IVB as defined by AJCC staging system for NPC, eighth edition) or recurrent\u002Fmetastatic NPC that is not amenable to local regional treatment or curative treatment and at least 6 months after radical treatment；\n5. Has not received prior systemic treatment;\n6. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status\n7. Subject must have a measurable target lesion based on RECIST v1.1;\n\nExclusion Criteria:\n\n1. Allergic to monoclonal antibodies, any cadonilimab components, gemcitabine, cisplatin, and other platinum drugs;\n2. Prior therapy as follow:\n\n   Anti-PD-1, anti-PD-L1 or anti-CTLA-4; Concurrent medical condition requiring the use of cortisol (\\>10mg\u002Fday Prednisone or equivalent dose) or other systematic immunosuppressive medications within 14 days before the study treatment（Except：inhalation or topical corticosteroids）.\n3. Any active malignancy ≤ 2 years before randomization except for specific cancer under investigation in this study and any locally recurring cancer that has been treated curatively (eg, resected basal or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix or breast)；\n4. Female patients who are at pregnancy or lactation.","65 Years",{"count":170,"type":21},20,[172,173],"PHASE1","PHASE2","This study is a single-arm, multicenter clinical study to evaluate the efficacy and safety of Cadonilimab in combination with gemcitabine\u002Fcisplatin as a first-line treatment for recurrent or metastatic nasopharyngeal carcinoma.",[176,177],"Nasopharyngeal Carcinoma","Immune Checkpoint Inhibitors","2023-06-01",{"date":180,"type":36},"2023-06-12",{"date":182,"type":21},"2023-08-01",{"date":184,"type":21},"2026-07-31",{"name":42,"class":43},""]